AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

Each month, we take a close look at an aspect of sector investing. This month, we are examining growth and valuation. Investors hunting for stocks that reasonably balance long-term growth ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and recent operational highlights for the third quarter ended September 30, 2024.